LAUSR

Gene therapy offers an alternative and promising avenue to lung cancer treatment. Here, we used dibenzocyclooctyne (DBCO)‐branched primers to construct a PTEN gene nanovector (NP‐PTEN) through branch‐PCR. NP‐PTEN showed the nanoscale structure with biocompatible size (84.7±11.2 nm) and retained the improved serum stability compared to linear DNA. When transfected into NCI‐H1299 cancer cells, NP‐PTEN could overexpress PTEN protein to restore PTEN functions through the deactivation of PI3K‐AKT‐mTOR signaling pathway to inhibit cell proliferation and induce cell apoptosis. The apoptosis rate of NCI‐H1299 cancer cells could reach up to 54.5 %±4.6 % when the transfection concentration of NP‐PTEN was 4.0 μg/mL. In mice bearing NCI‐H1299 tumor xenograft intratumorally administrated with NP‐PTEN, the average tumor volume and tumor weight was separately reduced by 61.7 % and 63.9 %, respectively, compared with the PBS group on the 18th day of administration. The anticancer efficacy of NP‐PTEN in NCI‐H1299 tumor xenograft suggests the promising therapeutic potential of branch‐PCR assembled PTEN gene nanovectors in lung cancer gene therapy and also provided more opportunities to introduce two or more tumor suppressor genes as an all‐in‐one gene nanovector for multiple gene‐based cancer gene therapy.